

Author Index

(Page numbers in *italics* refer to abstracts)

A

Abe T, 688
Abraham GN, *134, 135*
Adams LE, 217
Agarwal A, 525
Aidem HP, 532
Alarcon-Segovia D, 776
Alea JA, *549*
Alepa FP, *132*
Allen FH Jr, *573*
Altman RD, *113, 129, 171, 179*
Amstutz HC, 533
Anderson CH, *114*
Anderson L, *122*
Andreis M, *121, 572*
Andrews R, *136*
Angevine CD, 102, 278
Ansell BM, *130, 281*
Aptekar RG, 446, 461, *533, 572, 715*
Arnett FC, *546*
Arnold PI, *131*
Arnold WD, *549*
Asofsky R, *544*
Atkinson JP, 461
Atra E, 59
Attias M, *383, 719*
Atwater EC, 102
Avioli LV, *552*

B

Babcock J, *557*
Bacon PA, *533*
Bagby GC Jr, 665
Bagby MK, 163
Baker J, 397
Baker M, *120, 507*
Ballas M, 251
Baragar FD, *558*
Bardana EJ, *552*
Barnett E, 563
Barnett EV, 537

Barr JH Jr, 525

Barry DW, *550*
Baum J, 139, 278
Baumgartner WA, *534*
Beasley RP, *737, 743*
Beck F, *577*
Becker KE, *550*
Bell DA, *114*
Benedek TG, *578*
Bennahum DA, *534*
Bennett PH, *114, 743*
Bennett RM, 186, 298
Benson MD, *115, 535*
Bentwich ZH, *138*
Bernstein B, *535*
Bertino JR, 79
Bias WB, *546*
Billings S, 148
Binette JP, *536*
Blau SP, 428, 777
Bluestone R, *241, 533, 537, 568, 576*
Boisseau VC, *552*
Bole GG Jr, *137, 231*
Boys RA, *557*
Brand A, *576*
Brandt K, *115, 116, 547*
Brandt KD, *487, 535*
Bress NM, *541*
Britton MC, 629
Broder I, 225
Brown JC, *560*
Brunner CM, *120*
Bujek JS, 715
Burch F, 491
Burkhalter E, 428
Burstein AH, 397

C

Calabro JJ, *117, 282, 536, 573*
Caldwell JR, *537*
Calkins E, *536*
Campion DS, *537*

Cannon PJ, 556
Cannon RB, 393
Carlson RP, 575
Carr RI, 552
Carroll PE Jr, 557
Casarella W, 556
Case D, 556
Cassidy JT, 574
Cathcart E, 547
Cathcart ES, 115, 535, 566, 567
Caughey DE, 695
Chase G, 134
Cheatum DE, 545, 670
Chinea G, 564
Christian CL, 548, 555, 568
Chu EW, 461
Chused TM, 561
Claypool R, 574
Clemente E, 122
Clements P, 537
Cohen A, 115, 547
Cohen AS, 115, 116, 324, 487, 535
Cole BC, 191
Coleman M, 548
Convery FR, 117
Cooke TDV, 538

Cooperating Clinics Committee of the American Rheumatism Association, 353
Coplon NS, 117
Cousar JB, 539
Cox MB, 540
Cracchiolo A III, 533
Cunningham JE, 576
Curtis JE, 34

D

Dale DC, 657
D'Ambrosia RD, 539
Daniels T, 574
Davis GL Jr, 52
Davis JS IV, 52, 120
Davis W, 397
Decker JL, 89, 120, 313, 345, 446, 461, 507, 533, 572, 715, 765, 776
Denardo G, 539
Dennis MV, 287
Deshmukh K, 560
Diamond H, 546
Diamond HS, 131, 539
Dilley J, 554
Dismuke SE, 118

Doneson IN, 499
Dorwart BB, 540, 543
Douglas SD, 241
Dubois EL, 540, 560
Dwyer JM, 455

E

Eddie-Quartey AC, 186
Edgington TS, 578
Ehrlich GE, 259
Eisenbeis CH Jr, 525
Ellefson RD, 759
Engleman EP, 21, 30, 569
Epstein WV, 43
Erbe RW, 555
Esterly J, 134
Estes D, 59
Evans AS, 526

F

Fauci AS, 657
Ferguson JL, 139
Finerman GAM, 533
Ford DK, 341
Fotino M, 137
Fox IH, 545
Fraga A, 541
Franck WA, 541
Frank MM, 120, 507
Frankel VH, 397
Franklin EC, 123, 565, 576
Frantz MM, 313
Frayha RA, 542
Fries JF, 117, 154, 542, 629
Friou GJ, 555, 560, 564
Frizzell J, 126
Frost HM, 272

G

Gall EP, 543
Garcia-Kutzbach A, 118, 543
Garg SL, 117, 536
Gatter RA, 544
Gelfand MC, 118, 544

George S, 575
 Gerber DA, 126
 Gershon SL, 545
 Gerwin RD, 120, 507
 Gilbert RJ, 30
 Gilliam JN, 545
 Ginsberg B, 199
 Ginzler E, 546
 Girard DE, 665
 Giuliano V, 554
 Giuliano VJ, 119
 Gocke DJ, 568
 Goldberg L, 562
 Goldberg LS, 241, 533, 576
 Goldberg MA, 546
 Goldenberg DL, 487, 547
 Goldman M, 539
 Gordon DA, 225, 305, 411
 Gottlieb NL, 131
 Gough WW, 548
 Graham DR, 272
 Granda JJ, 549
 Grayzel AI, 419
 Green FA, 549
 Greenspan J, 574
 Greenwald RA, 549
 Grimley PM, 313, 550
 Grossman A, 553
 Gruber CM Jr, 635
 Gupta N, 550
 Gupta RC, 363
 Gutman AB, 431
 Guttman GG, 259

Hassan M, 556
 Hawker CD, 590
 Healy LA, 426, 570, 737, 775
 Henrard J, 114
 Henson PM, 208
 Herman JH, 287
 Hersh EM, 34
 Hess E, 569
 Hess EV, 217
 Hilgartner MW, 549
 Hill VA, 534
 Hirshau Y, 97, 126, 701
 Hoffman AA, 552
 Hoffstein S, 132, 138, 606
 Holborow EJ, 130
 Holland PV, 406
 Hollander JL, 771
 Hollister JR, 10
 Holman H, 542, 569
 Holman HR, 154, 554
 Holt PJL, 136, 186, 298
 Homma M, 688
 Hopper K, 114
 Hopps HE, 446
 Horwitz DA, 120, 539
 Howell DS, 129, 171, 179
 Huffer WE, 363
 Hunter D, 554
 Hurd E, 139
 Hurd ER, 84, 119, 545, 554, 670
 Hurwitz D, 555

H

Haakenstad AO, 551
 Hadler NM, 507, 541
 Hahn B, 561
 Hahn BH, 120, 163, 552
 Hahn TJ, 552
 Halder NM, 120
 Hamilton TR, 120, 163
 Hansell JR, 540
 Hanson V, 535
 Hara M, 688
 Harbeck RJ, 552
 Harris ED Jr, 126, 552, 573
 Harris ER, 553
 Harrison WE Jr, 553
 Harvey JP Jr, 562

Ignarro LJ, 560
 Irvin W, 569
 Irvin WS, 566
 Ishikawa H, 121

J

Jackson J, 122
 Jacox R, 135
 Jacox RF, 102, 278
 James PG, 21
 Jasen HE, 119, 122, 133
 Johnson CC, 113
 Johnson GJ, 130

Johnson JS, 1, 578
Jurist JM, 66

K

Kagen LJ, 555
Kaplan D, 131, 546
Kaplan MH, 122
Kaplan SR, 123
Kazmar R, 575
Keiser H, 199, 468
Kelley WN, 127
Khairi MRA, 113
Kimball AC, 555
Kimball HR, 345
Klinenberg JR, 537
Kobayashi I, 471
Koga T, 563
Kotani S, 563
Kourounakis L, 71
Kraj MA, 578
Krane SM, 555
Krey PR, 324
Krugmire RB Jr, 117
Ku LC, 564
Kunkel HG, 137, 138
Lupusta MA, 71

L

Leeb JE, 534
Leonard DR, 552
LeRoy EC, 270, 556, 559, 619
Levin M, 123
Levine L, 129
Levy J, 537, 562
Levy RM, 556
Lewis D, 139
Lewis SM, 298
Liang GC, 10, 557
Lidsky MD, 34, 148
Lies RB, 369, 597
Lightfoot RW Jr, 548, 549
Lin W, 126
Linke R, 123
Little HA, 305
Littleton C, 125
Litwin A, 217
Lockshin MD, 499, 568
Lorber A, 534, 557
Louria DB, 276
Lynch JA, 124

M

Machleder HI, 562
Mackay IR, 455
Mackenzie MR, 558
Malawista SE, 749
Man SC, 558
Mandell B, 577
Mannik M, 10, 551
Marchesano JM, 536
Marcus RE, 646
Margolis HM, 525, 578
Maricq HR, 619
Martens M, 397
Martin JR, 553
Martinez VA, 127, 705
Masi AT, 118, 543, 567
Mattioli M, 124
May C, 569
Mayor M, 397
McCarty DJ, 132, 570
McCluskey RT, 549
McDevitt HO, 154
McDuffie F, 569
McIntosh RM, 563
McManus J, 217
McWhorter JE, 559
Medsger TA Jr, 578
Meilman E, 577
Messner RP, 369, 534, 597
Meyer HM Jr, 446
Meyer KF, 21, 30
Michelitch JH, 313
Mikkelsen WM, 359
Miller EJ, 128
Miller ML, 491
Millman I, 543
Mintz G, 541
Miyawaki S, 726
Montoye HJ, 359
Moore A, 137
Morris A, 134
Morris AD, 125
Moskowitz RW, 397
Mueller MN, 66
Muniz OE, 171

N

Nagle R, 544
Nankin HR, 135
Narita T, 563
Nastro L, 562
Natali PG, 579

Natvig JB, 573
Nelson RA Jr, 71
Nies KM, 560
Nimni ME, 560

O

Ogryzlo MA, 411
Oronsky AL, 560, 564
Orozco J, 541
Osterland CK, 120, 163, 561

P

Pan SF, 135
Parker L, 561
Parker LM, 561
Parkman P, 126
Parrino GR, 536
Patzakis MJ, 562
Paulus HE, 550, 562
Pearce D, 537
Pearson CM, 241, 533, 550, 562, 563, 568
Peltier A, 59
Penso JS, 563
Peppercorn M, 406
Perper RJ, 560, 564
Pershellin RH, 564
Person DA, 125, 677
Peter JB, 562
Petty RE, 574
Phelps F, 590
Phillips P, 126
Phillips PE, 97, 701
Pillarisetty R, 573
Pinals RS, 126
Pinnell SR, 555
Pita JC, 171, 179
Pless IB, 278
Plotz PH, 345, 406
Pollock BH, 525
Popovtzer MM, 363
Postlethwaite AE, 127
Powell M, 574
Powers TR, 569
Pras M, 123
Pruzanski W, 411

Q

Quismorio FP, 560, 564
Quismorio FP Jr, 555

R

Ramsdell CM, 127
Ransom JC, 122
Rawls WE, 125, 677
Reginato AJ, 127, 705
Reichlin M, 124
Retaillau H, 737
Rich RR, 1
Richardson JA, 265
Richer SM, 538
Richmond JD, 544
Ricketts H, 702
Ridolfo AS, 635
Riggins RS, 539
Ritchie RF, 726
Roberts SP, 720
Robertson PB, 128
Robin JA, 128
Robinson DR, 129, 541
Rodda BE, 635
Rodman GP, 268
Rodnan GP, 128, 135
Rogers B, 577
Rosenthal CJ, 565
Rosenthal M, 572
Roth H, 446
Rowley MJ, 455
Rubin A, 635
Ryan WE, 759

S

Salisbury KW, 406
Samaha RJ, 566
Sammareco J, 397
Sanda M, 561
Sapolsky AI, 129
Scarola JA, 542
Schachter J, 21, 30
Schaff Z, 550
Schaller J, 130
Scheinberg MA, 566, 567
Scherer AT, 567
Schlosstein L, 568
Schmid FR, 393, 569
Schnapp JJ, 499
Scholar EM, 123
Schultz DR, 131
Schumacher HR, 127, 540, 543, 705
Schur PH, 122, 544
Schwartz CE, 549
Senter RG, 720

Sargent JS, 568
Sharon E, 131, 539, 546
Sharp G, 134, 569
Sharp GC, 125, 154
Sharp JT, 34, 125, 148, 677
Shen AC, 569
Sherman RL, 548
Shoop JD, 534
Shulman LE, 542, 546
Siegal FP, 138
Siegel RC, 117
Silcox DC, 132, 570
Simkin PA, 557, 570, 702
Simsarian JP, 446
Simson J, 526
Skeith MD, 570
Skinner M, 115, 116
Sledge CB, 376
Sliwinski AJ, 132, 388
Smiley JD, 341
Smiley WK, 130
Smith CB, 191
Smith DE, 21
Smith FG Jr, 563
Smith H, 129
Smyth CJ, 363
Smythe HA, 411
Soberman RJ, 132
Spilberg I, 133, 571
Stastny P, 121, 572
Steinberg AD, 92, 118, 406, 533, 544, 561, 572
Stevens JG, 533
Steward MW, 573
Stillman JS, 106, 122
Stobo JD, 118
Stolzer BL, 525
Strandness DE Jr, 117
Strosberg JM, 573
Strunk SW, 670
Sugai S, 573
Sullivan DB, 574
Sumner DS, 702
Sylvester R, 574
Sylvester RA, 383, 719

T

Tabbara K, 574
Takahashi M, 535
Talal N, 345, 383, 422, 573, 574, 719
Tan EM, 579
Tan M, 43
Tateishi H, 133

Taylor H, 134
Taylor J, 134
Terasaki P, 568
Terasaki PI, 560
Tesar J, 575
Thoburn R, 137
Thompson J, 562
Tolchin S, 128
Tolchin SF, 135
Trieshmann H, 135
Tse RL, 136
Tuffanelli DL, 383
Turner MW, 573

V

Van Arman CG, 575
Vance SE, 564
Vaughan JH, 114, 578
Versey J, 136
Virshup AM, 388

W

Wakem CJ, 695
Walker SE, 137, 231
Walsh JR, 665
Ward JR, 191, 491
Ward LE, 759
Warrick P, 635
Waxman BA, 376
Waxman J, 491
Webb FW, 241
Weiner JM, 540
Weisbart R, 576
Weisman MH, 576
Weissmann G, 132, 138, 576, 606
Wernet P, 137
Weyl S, 542
Whitaker JN, 120, 507
Whitehouse M, 577
Whitehouse MJ, 569
Wiener S, 577
Wierzchowiecki M, 540
Wilkes RM, 446
Williams ED, 298
Williams RC Jr, 369, 597
Willkens RF, 743
Wiltse DW, 287

Winchester R.J. 138
Winkelstein A. 135
Woessner F.J. 129
Wolff SM. 345, 461, 657, 715
Wright DG. 749

Y
Yamasaki K. 688

Young RC. 569
Yu D. 577

Z

Zawadzki ZA. 578
Zeiders RS. 578
Ziff M. 119, 121, 122, 133, 139, 471, 545, 554, 572, 670
Zimmer H. 217
Zurier RB. 138, 251, 606
Zvaifler N.J. 576

I
N
C
E
X
I

Subject Index

(Page numbers in *italics* refer to abstracts)

A

Acromegaly, plasma PPi in, 132
Acupuncture, in rheumatoid arthritis, 569
 with painful knees, 558
Addiction to drugs, and intervertebral disc space infections, 562
Adenosine monophosphate, cyclic, effects on crystal-induced synovitis, 136
Adjuvant arthritis
 from bacterial cell walls, 563
 cobra venom factor affecting complement in, 71
 gold therapy in, affecting mitochondrial function, 534
 prostaglandin E₁ in, 251
 and suppression of inflammation in adrenalectomized rats by prostaglandins, 606
Adrenalectomized rats, suppression of inflammation in, by prostaglandins, 606
Age of onset, in juvenile RA, 574
Aging NZB/NZW mice, cellular immunity in, 118
Agitation, mechanical, effects in crystal-induced arthritis, 540
Alaskan Eskimos, rheumatoid arthritis in, 737
Albumin, serum, sodium rate binding to, 537
Allopurinol, single daily dose in gouty hyperuricemia, 128
American Rheumatism Association, presidential addresses, 106, 765
Amyloid fibrils
 nonimmunoglobulin component of, 123
 proteins in
 antigenicity of, 115
 homology with Bence-Jones protein, 116
Amyloidosis
 lymphocyte and macrophage function in, 567
 neuropathy in, 535
 and P-component in plasma, 536
 and Reiter's disease, fatal case of, 695
Anaphylaxis, and antigen deposition, parasympathetic blockade affecting, 556
Antibiotics, in experimental bedsonial arthritis, 30
Antibody formation. *See Immunology*
Arteritis, giant cell, diagnosis of, 702
Arthritis
 acute infectious, 118
 from gram-negative bacilli, staphylococci and streptococci, 547
 adjuvant-induced. *See Adjuvant arthritis*
 bacterial, in adults, 543
 bedsonial, experimental, 21, 30

crystal-induced. *See Crystal-induced disease*
destructive polyarthritis with *Mycobacterium kansassii* infection, 665
gonococcal, 715
hemophiliac, 549
from *Herpes simplex virus*, 241, 533
osteoarthritis. *See Osteoarthritis*
 psoriatic
 in children, 117, 278
 6-mercaptopurine in, 139
rheumatoid. *See Rheumatoid arthritis*
from 6-sulfanilamidoindazole, and induction of Shwartzman reaction, 491
Arthroplastics, replacement, for knee, 124, 532, 533
Aspirin. *See Salicylates*
Australia antigen
 and polyarteritis nodosa, 568
 and synovial membrane in hepatitis, 543
Autoimmune disease in NZB/NZW mice
 comparison of drugs in, 120, 163
 cyclophosphamide in, 134
 estrogens affecting, 231
 and tolerance to DNA, 567
Azathioprine
 chemical action and pharmacology of, 79
 complications from, 533
 glomerular deposits after, in NZB/NZW mice, 544
 and immune response to flagellin, 455
 immunosuppressive and antiinflammatory properties of, 84
 in lupus erythematosus, 546
 in lupus nephritis, 572
 in NZB/NZW nephritis, 120, 163
 in rheumatoid arthritis, double-blind crossover study of, 411, 776
 withdrawal of, in SLE, 131

B

Bacterial arthritis, in adults, 543
Bacterial cell walls, inducing polyarthritis, 563
Bedsonial arthritis, experimental, 21
 antibiotic therapy in, 30
Bence-Jones protein, and glycosaminoglycans in amyloid fibrils, 716
Bladder toxicity, from cyclophosphamide, 461

Bone
 status in rheumatoid arthritis, 66
 steroid-induced loss in RA, 552

Bone marrow, granulocyte reserves in rheumatic disease, 345

Book reviews
Acupuncture Therapy: Current Chinese Practice (Leong et al.), 779
Arthritis and Allied Conditions: A Textbook of Rheumatology (Hollander et al., eds.), 528
Beyond the Copper Bracelet: What You Should Know About Arthritis (Healy, Wilske & Hansen), 284
The Hand Book (Johnson), 703
Immunology, Immunopathology and Immunity (Sell), 284
The Radiology of Joint Disease (Forrester & Nesson), 779
The Truth About Arthritis Care (Calabro & Wykert), 703

Bowel symptoms, in spondylitis, 549

Brain scans, in lupus cerebritis, 534

C

Calcific periarthritis, in twins, 393

Calcinosis, in scleroderma, 542

Calcium pyrophosphate crystals
 deposition in ochronotic arthropathy, 705
 inflammation induced by, 133

Candida guilliermondii infection of knee, in RA, 272

Capillary abnormalities in fingers, in connective tissue disease, 619

Carcinoma of pancreas, with polyarthritis and subcutaneous nodules, 388

Cartilage
 antigenic components in RA, 287
 collagen fibrils affected by rheumatoid synovial collagenase, 552
 collagen susceptibility to collagenases, 128
 degradation by protease from leukocytes, 560
 in familial chondrocalcinosis, 127
 in ferritin-induced arthritis, 133
 localization of antigen to cartilage tissues, 538
 lysozyme interaction with proteoglycans, 549
 neutral enzyme activity in, 129
 normal and osteoarthritic, collagen metabolism in, 560
 osteoarthritic, proteoglycan degradation in, 179

Cathepsin D activity, in articular cartilage, 129

Cell-mediated immune response, in SLE, 688

Cellular immunity, in rheumatoid arthritis, 499

Cerebritis, lupus, brain scans in, 534

Cerebrospinal fluid
 DNA antibodies in, in SLE, 552
 fourth component of complement in, in SLE, 120, 507

Chemotaxis
 inhibition by complement depletion with cobra factor, 577
in vivo quantitation of, 564
 urate crystal-induced, 571

Chondrocalcinosis, articular, 171
 familial, cartilage in, 127
 with iron overload, 305
See also Pseudogout

Chondrocytes, low oxygen concentration affecting, 646

Chromosomes, cyclophosphamide affecting, 135

Clq-mediated precipitation of immune complexes, 558

Cobra venom factor
 affecting complement in adjuvant-induced disease, 71
 complement depletion by, and chemotaxis inhibition, 577

Colchicine
 affecting prostaglandin synthesis by synovial cultures, 129
 and enzyme release from leukocytes in phagocytosis, 749

Cold, effects in crystal-induced arthritis, 540

Colitis, ulcerative, and spondylitis, 549

Collagen
 cartilage, susceptibility to collagenases, 128
 hydroxylase in fibroblasts, and hydroxylysine deficiency, 555
 metabolism in normal and osteoarthritic cartilage, 560

Collagenase, rheumatoid synovial, affecting cartilage collagen fibrils, 552

Collagenous tissues of joints, trapping of immune complexes in, 122

Complement
 activation of alternate pathway by cryoglobulins, 575
 cobra venom factor affecting, in adjuvant-induced disease, 71
 depletion by cobra factor, and chemotaxis inhibition, 577
 efficient fixation by 7S IgM, 537
 fourth component in cerebrospinal fluid in SLE, 120, 507
 gold affecting functional activities of components, 131
 metabolism in RA, 136

Connective tissue disorders. *See* Rheumatic and connective tissue diseases

Corticosteroids
 bone loss from, in RA, 552
 and cell-mediated immunity in SLE, 565
 cortisol affecting enzyme release from leukocytes in phagocytosis, 749
 and enzyme release from leukocyte lysosomes, 564
 and lupus nephritis in children, 563

Counterimmunoelectrophoresis, for detection of circulating DNA, 52

Cricoarytenoid joint, in rheumatoid arthritis, 553

Cryoglobulinemia
 in infectious endocarditis, 555
 monoclonal IgG, vasculitis with, 548

Cryoglobulins, and activation of alternate pathway of complement, 575
Crystal-induced disease
from calcium pyrophosphate crystals, 733
and effects of heat, cold, and mechanical agitation, 540
See also Urate crystals
Cyclophosphamide
affecting lymphocytes in connective tissue diseases, 554
autoantibody response to, and lymphoma development in mice, 137
bladder toxicity from, 461
chemical action and pharmacology of, 79
chromosome abnormalities from, 135
complications from, 533
dosage in connective tissue diseases, 120
glomerular deposits from, in NZB/NZW mice, 544
and immune response to flagellin, 455
immunosuppressive and antiinflammatory properties of, 84
in lupus erythematosus, 154
in lupus nephritis, 572
in NZB/NZW nephritis, 720, 134
lymphocyte deactivation of metabolites of, 577
in polymyositis, 154
in rheumatoid arthritis, 148
immune response to, 34
and tolerance to DNA in NZB/NZW mice, 561
and tumor development, 524
in Wegener's granulomatosis, 657
Cysts, antecubital, in RA, valvular mechanisms in, 259
Cytocalasin B, and lysosomal enzyme release from leukocytes, 138
Cytotoxic drugs, in rheumatic diseases, 92

D

Death in SLE, causes of, 540
Degenerative joint lesions, after partial meniscectomy, 397
Dermatomyositis
finger capillary abnormalities in, 619
muscle ischemia in, 567
Disodium etidronate, in Paget's disease, 113
DNA
antibodies to, in SLE, 114, 199, 554
circulating, detection with counterimmunoelctrophoresis, 52
extractable nuclear antigen affecting anti-DNA reaction, 125
native
antibodies to, in SLE sera, 199
cellular response to, in macrophage inhibitory test, 688
labeled with iodine-125, in radioimmunoassay, 468
strandedness of, and reactivity with sera, 566

tolerance to, in autoimmune disease of NZB/NZW mice, 561
Drainage
surgical, in acute infectious arthritis, versus medical treatment, 547
of thoracic duct lymphocytes, in RA, 562
Drug addiction, and intervertebral disc space infections, 562
Drug studies, organization of, 428

E

Elbow, antecubital cysts in RA, valvular mechanisms in, 259
Endocarditis, infectious, cryoglobulinemia in, 555
Endotoxin, adsorbed in urate crystals, and gout induction, 575
Enzymes
activity in articular cartilage, 129
lysosomal
corticosteroids affecting release of, 564
release from leukocytes, agents affecting, 138, 749
release by monosodium urate, 132
release from neutrophils in phagocytosis, 208
synovial acid phosphatase in rheumatoid diseases, 376
Epstein-Barr virus antibody, in SLE, 97
Eskimos, Alaskan, rheumatoid arthritis in, 737
Estrogens, affecting autoimmune disease in NZB/NZW mice, 231

F

Familial conditions
calcific periarthritis in twins, 393
SLE in male siblings, 221
Febrile juvenile RA, acute, 536
Felty's syndrome, marrow granulocyte reserves in, 345
Femoral head circulation, scanning studies of, 539
Fender-kicker syndrome, 102
Fenoprofen
interactions with aspirin, 635
in rheumatoid arthritis, 629
Ferritin-induced arthritis, electron microscopy of, 133
Fertility, and lupus erythematosus, 541
Fetal wastage, and lupus erythematosus, 541
Fibrils
amyloid. *See* Amyloid fibrils
of cartilage collagen, affected by rheumatoid synovial collagenase, 552
Finger capillary abnormalities, in connective tissue disease, 619

Flagellin, immune response to, drugs affecting, 455
Foot, fender-kicker syndrome of, 102
Fractures, metatarsal, in fender-kicker syndrome, 102

G

Generic equivalents, 775
Genetic control of salicylate metabolism, 550
Genetic studies, in ankylosing spondylitis, 573
Geometric knee prosthesis, 532, 533
Giant cell arteritis, diagnosis of, 702
Glomerular deposits, after drug therapy of NZB/NZW mice, 544
Glycypyrrolate, affecting uric acid levels, 127
Glycosaminoglycans, in amyloid fibrils, homology with Bence-Jones protein, 716
Gold therapy
and functional activities of complement components, 131
and metabolism of gold in lactation, 777
and mitochondrial function in adjuvant arthritis, 534
in rheumatoid arthritis, 353
weekly injections in, 557
Gonococcal arthritis, 715
Gout
induced with urate with adsorbed endotoxin, 575
polyarticular, 541
progress in knowledge of, 431
Gouty hyperuricemia, single daily dose of allopurinol in, 128
Gram-negative bacilli, acute infectious arthritis from, 547
Granule enzymes. *See* Enzymes, lysosomal
Granulocyte reserves in marrow, in rheumatic diseases, 345
Granulomatosis, Wegener's, cyclophosphamide in, 657
Gutman, Alexander, 522

H

Hageman factor, and urate crystal-induced arthritis, 577
Heart
infectious endocarditis, cryoglobulinemia in, 555
pathogenesis of rheumatic valvular disease, 122
pericardial disease in scleroderma, 559
studies in juvenile RA, 535
Heat, effects in crystal-induced arthritis, 540
Hemochromatosis, arthropathy of, 305
Hemodialysis and transplantation
in lupus nephritis, 117
for renal failure in scleroderma, 265
Hemophilic arthritis, 549
Hepatitis
synovial membrane in, and Australia antigen, 543
with tuberculosis and SLE, 406

Hepatotoxicity of salicylates, in juvenile RA, 1
Heroin addicts, intervertebral disc space infections in, 562
Herpes simplex virus, arthritis from, 241, 533
Hip replacement, and thromboembolic disease, 117
Histidine, in rheumatoid arthritis, 126
Histonase activity, in articular cartilage, 129
HL-A antigens
in lupus erythematosus, 546
and lymphocytotoxic antibodies in SLE, 560
W27 specificity and ankylosing spondylitis, 568
Hydralazine urinary metabolites, in SLE, 217
Hydroxylysine deficient collagen, and collagen hydroxylase in fibroblasts, 555
Hyperostosis of spine, in Pima Indians, 714

I

Immune complexes, in synovial fluid, 10
Immune response to cyclophosphamide, in RA, 34
Immunofluorescence
of antigammaglobulin antibody, 59
of thymocytotoxic antibody, 567
Immunoglobulins
abnormalities in RA, 578
deposits in skin in SLE, 564
IgG
antigens interacting with low affinity rheumatoid factors, 573
in juvenile RA, 126
IgM, and complement fixation, 537
molecular basis of interaction with biomembranes, 576
in temporal arteries, 557
Immunology
antibodies to DNA in CSF, in SLE, 552
antibodies in DNA and RNA in SLE, 554
antibodies to extractable nuclear antigen, 125, 569
antibodies to reovirus RNA in SLE, 383, 719
antibody-like material in lupus erythematosus, 43
antibody titers in SLE, 526
anti-DNA antibody forming cells in SLE, 114
antigen dependency of migration inhibitory factor, 576
antigenicity of amyloid fibril proteins, 715
antinuclear antibodies
in iridocyclitis and JRA, 130
in NZB/NZW mice, after estrogen, 231
antinucleolar antibody, in rheumatic diseases, 726
assay for antibodies to nDNA in SLE sera, 199
Australia antigen
and polyarteritis nodosa, 568
and synovial membrane in hepatitis, 543
autoantibody response in NZB/NZW mice after cyclophosphamide, 137
blockage of lymphocyte surface antigens in SLE, 137
cartilage antigenic components in RA, 287

cell-mediated immune response in SLE, 688
after steroid therapy, 565
cellular immunity
in aging NZB/NZW mice, 118
in rheumatoid arthritis, 499
changes in hemophilic arthritis, 549
Clq-mediated precipitation of immune complexes, 558
cultured B-immunocytes from rheumatoid synovium, 341
Epstein-Barr virus antibody in SLE, 97
HL-A antigens. *See* HL-A antigens
humoral antibody to flagellin, drugs affecting, 455
localization of antigen to cartilage tissues, 538
lymphocytotoxic antibody activity of sera in SLE, 369
monoclonal IgG cryoglobulinemia, with vasculitis, 548
nonimmunoglobulin component of amyloid fibrils, 123
parasympathetic blockade affecting anaphylaxis and antigen deposition, 556
pathogenesis of vasculitis in RA, 576
RNA protein antigen in SLE serum, 124
saturation of RES by immune complexes, 551
thymocytotoxic antibody of NZB mice, 561
trapping of immune complexes in joint collagenous tissues, 122
triclonal rheumatoid factor gammopathy, 135
virus antibody and IgG levels in juvenile RA, 126
See also Autoimmune disease in NZB/NZW mice
Immunosuppressive drugs, in rheumatic diseases, 92
Immunosuppressive effects of B-lymphocytes in RA, 537
Indians
Pima, hyperostosis of spine in, 114
Yakima, rheumatoid arthritis in, 743
Infectious arthritis, 118, 191
from gram-negative bacilli, staphylococci, and streptococci, 547
medical treatment versus surgical drainage, 547
Intellectual achievement, and serum uric acid, 359
Intervertebral disc space infections, in heroin addicts, 562
Iodine-125, for labeling of native DNA, 468
Iridocyclitis, in juvenile RA, 130
antinuclear antibodies in, 130
Iron
overload with chondrocalcinosis, 305
synovial deposition in RA, 298
Iron-binding protein, in synovial fluid, 186
Ischemia, in polymyositis muscle, 567

J

Joints
cartilage conditions. *See* Cartilage
degenerative lesions after partial meniscectomy, 397
polyarticular gout, 541
rheumatoid, lymphokines in, 572

trapping of immune complexes in collagenous tissues of, 122

K

Kidney
comparison of three drugs in NZB/NZW nephritis, 120
hemodialysis and transplantation
in lupus nephritis, 117
in scleroderma, 265
in lupus erythematosus, 670
lupus nephritis in children, after steroid therapy, 563
in scleroderma, 556
suppression of uric acid secretion in renal hypouricemia, 570

Knee
Candida infection of, in RA, 272
degenerative lesions after partial meniscectomy, 397
osteoarthritis of, intraosseous venography in, 124
pain in RA, acupuncture affecting, 558
replacement of, 124
with geometric prosthesis, 532, 533
with polycentric prosthesis, 533

L

Lactation, gold metabolism in, 777
Lactoferrin, in synovial fluid, 186
Leukocytes
enzyme release from
corticosteroids affecting, 564
cytochalasin B affecting, 138
in phagocytosis, agents affecting, 749
inhibition of mixed culture responses by sera from rheumatic disease patients, 597
protease from, cartilage degradation by, 560
in Wegener's granulomatosis, cyclophosphamide affecting, 657
Lipid synovial effusion in SLE, 759
Liver damage, from salicylates in juvenile RA, 1
See also Hepatitis
Lupus erythematosus
discoid, and antibodies to viral RNA, 383
systemic
and abnormal structures in lymphocytes, 313
and antibodies to DNA and RNA, 554
and antibodies to native DNA in sera, 199
and antibodies to reovirus RNA, 719
antibody-like material in, 43
antibody titers in, 526
anti-DNA antibody forming cells in, 114
azathioprine in, 546

and B and T cell lymphopenia, 566
blockage of lymphocyte surface antigens in, 737
causes of death in, 540
cell-mediated immune response in, 565, 688
cerebritis in, brain scan of, 534
complications from cytotoxic agents in, 533
cyclophosphamide in, 154
and DNA antibodies in CSF, 552
and effects of cyclophosphamide on lymphocytes, 554
Epstein-Barr virus antibody in, 97
experimental skin lesions resembling, 579
finger capillary abnormalities in, 619
fluorescent band test in, prognostic significance of, 545
and fourth component of complement in CSF, 120, 507
histocompatibility antigens in, 546, 560
hydralazine urinary metabolites in, 217
and immunoglobulin deposits in skin, 564
and inhibition of lymphocyte activation by sera, 539
and inhibition of mixed culture responses by sera, 597
kidney in, 670
and lipid synovial effusion, 759-
lymphopenia in, 119
lymphocytotoxic antibodies in, 369, 560
in male siblings, 221
marrow granulocyte reserves in, 345
and pregnancy, 541
prognosis in, 542
and RNA protein antigen in sera, 124
unique presentation of, 428-
with viral hepatitis and tuberculosis, 406-
and withdrawal of azathioprine, 131
Lupus-like tubular structure, in lymphoid cells, 550
Lupus nephritis
in children, after steroid therapy, 563
cyclophosphamide or azathioprine in, 572
hemodialysis and transplantation in, 117
Lymphocytes
abnormal structures in SLE, 313
blockage of surface antigens in SLE, 737
culture of B-immunocytes from rheumatoid synovium, 341
cyclophosphamide affecting, in connective tissue diseases, 554
deactivating cyclophosphamide metabolites, 577
function in amyloidosis, 567
heterogeneity and function of, 422
immunosuppressive effects of B cells in RA, 537
inhibition of activation by SLE sera, 539
nucleic acid enzyme levels in, in RA, 123
proportion of B and T cells in RA joint fluids, 138
in synovial fluid, in early RA, 544
T cells in rheumatic diseases, 578
thoracic duct, drainage in RA, 562
Lymphocytotoxic antibodies
activity of sera in SLE, 369
and HL-A antigens in SLE, 560

Lymphoid cells
lupus-type tubular structures in, 550
in rheumatoid synovium, 471
Lymphokines
inducing synovitis, 121
in rheumatoid joints, 572
Lymphoma
and monoclonal macroglobulins in NZB/NZW mice, 573
in NZB/NZW mice, after cyclophosphamide, 137
Lymphopenia, in lupus erythematosus, 119, 566
Lysosomes, enzyme release from. *See* Enzymes, lysosomal
Lysozyme, cartilage, interaction with proteoglycans, 549

M

M-components in serum, and amyloidosis with neuropathy, 535
Macroglobulins, monoclonal, and lymphoma in NZB/NZW mice, 573
Macrophage
function in amyloidosis, 567
inhibitory test, and cellular response to native DNA, 688
Meniscectomy, partial, inducing degenerative lesions, 397
6-Mercaptopurine, in psoriatic arthritis, 139
Metatarsal fractures, in fender-kicker syndrome, 102
Methotrexate
chemical action and pharmacology of, 79
immunosuppressive and antiinflammatory properties of, 84
Mexican medicine, comments on, 426, 776
Migration inhibitory factor, antigen dependency of, 576
Mitochondrial function, gold therapy affecting, in adjuvant arthritis, 534
Muscle ischemia, in polymyositis, 567
Mycobacterium kansasii infection, and destructive polyarthritis, 665
Mycoplasmas
in connective tissue diseases, 125, 677
in rheumatoid tissue, 191

N

Nephritis
lupus. *See* Lupus nephritis
in mice. *See* Autoimmune disease of NZB/NZW mice
Neuropathy, in amyloidosis, 535
Neutrophils, release of granule enzymes from, in phagocytosis, 208
Nicotinic acid, affecting uric acid metabolism, 545
Nodules, subcutaneous, with polyarthritis and carcinoma of pancreas, 388

Nuclear antigen, extractable, antibodies to, 125, 569
Nucleic acids, enzyme levels in lymphocytes in RA, 123
Nucleolus, antibody to, in rheumatic diseases, 726

O

Ochronotic arthropathy, with calcium pyrophosphate crystal deposition, 705
Osteitis deformans, disodium etidronate in, 113
Osteoarthritis
and acid phosphatase in synovium, 376
and collagen metabolism in cartilage, 560
and degradation of proteoglycans in cartilage, 179
of knee, intraosseous venography of, 124
plasma PPi in, 132
and synovial fluid inorganic phosphate levels, 570
Osteoporosis, regional migratory, 363
Oxygen, low concentration of, affecting chondrocyte cultures, 646

P

P-component in plasma, purification of, 536
Paget's disease, disodium etidronate in, 113
Pancreas, carcinoma of, with polyarthritis and subcutaneous nodules, 388
Parasympathetic blockade, and anaphylaxis and antigen deposition in rat, 556
Parathyroid hormone levels, in pseudogout, 590
Peptide, rheumatoid factor-reactive, 134
Periarthritis, calcific, in twins, 393
Pericardial disease, in scleroderma, 559
Phagocytosis
and enzyme release from leukocytes, agents affecting, 749
inhibiting factor in RA serum, 132
and release of granule enzymes from neutrophils, 208
Phalangeal fractures of foot, in fender-kicker syndrome, 102
Phosphate, inorganic, synovial fluid levels in pseudogout and osteoarthritis, 570
Polyarteritis nodosa, and Australia antigen, 568
Polyarthritis
destructive, with *Mycobacterium kansasii* infection, 665
induction with bacterial cell walls, 563
with subcutaneous nodules and carcinoma of pancreas, 388
Polyarticular gout, 541
Polymyositis
cyclophosphamide in, 154
and toxoplasmosis, 555
Prednisolone, in NZB/NZW nephritis, 120, 163
Pregnancy, and lupus erythematosus, 541
Prognosis in SLE, 542

Prostaglandins
PGE₁ in adjuvant arthritis, 251
and suppression of inflammation in adrenalectomized rats, 606
synthesis by synovial cultures, colchicine affecting, 129
Prostheses, for knee, 532, 533
Protease
activity in articular cartilage, 129
from leukocytes, cartilage degradation by, 560
Protein
in amyloid fibrils. *See* Amyloid fibrils
iron binding, in synovial fluid, 186
Proteoglycans
cartilage lysozyme interaction with, 549
degradation in osteoarthritic cartilage, 179
Pseudogout, 171
parathyroid hormone levels in, 590
plasma PPi in, 132
and synovial fluid inorganic phosphate levels, 570
Psoriatic arthritis
in children, 117, 278
6-mercaptopurine in, 139
Pyogenic infection, and bacterial arthritis, 543
Pyrazinamide suppression test, 539
Pyrophosphate, inorganic, in biologic fluids, 132
in pseudogout, 171

R

Radioimmunoassay
for antibodies to reovirus RNA in SLE, 719
and labeling of native DNA with iodine-125, 468
Reiter's syndrome
and amyloidosis, fatal case of, 695
and experimental bedsonian arthritis, 21, 30
Reovirus RNA, antibodies to, in SLE, 383, 719
Reserpine, intraarterial, 526
Reticuloendothelial system, saturation by immune complexes, 551
Rheumatic and connective tissue diseases
antinuclear antibody in, 726
cyclophosphamide dosage in, 120
finger capillary abnormalities in, 619
T lymphocytes in, 578
valvular, pathogenesis of, 122
viruses and mycoplasma in, 125, 677
Rheumatoid arthritis
and acid phosphatase in synovium, 376
acupuncture in, 569
for knee pain, 558
in Alaskan Eskimos, 737
azathioprine in, double-blind crossover study of, 411, 776
and *Candida* infection of knee, 272
cartilage antigenic components in, 287

cellular immunity in, 499
complement metabolism in, 136
complications from cytotoxic agents in, 533
cricoarytenoid joint in, 553
and culture of B-immunocytes from synovium, 341
cyclophosphamide in, 148
 immune response to, 34
dysimmunoglobulinemias in, 578
early, synovial fluid lymphocytes in, 544
and effects of cyclophosphamide on lymphocytes, 554
fenoprofen calcium in, 629
finger capillary abnormalities in, 619
 gold salt therapy in, 353
 histidine in, 126
immunosuppressive effects of B-lymphocytes in, 537
infectious etiology of, 191
 and inhibition of mixed culture responses to virus, 597
juvenile
 acute febrile, 536
 adult onset of, 715
 ages of onset in, 574
 iritidocyclitis in, 130
 salicylate hepatotoxicity in, 1
 Sjogren's syndrome in, 122
 studies of cardiac involvement, 535
 virus antibody and IgG levels in, 126
 and virus replication in cultured synovial cells, 114
and lymphoid cells in synovium, 471
and lymphokines in joints, 572
marrow granulocyte reserves in, 345
Mexicali treatment of, 426
 and nucleic acid enzyme levels in lymphocytes, 123
 and phagocytosis inhibiting factor in serum, 132
proportion of B and T lymphocytes in joint fluids, 138
and reconstruction of wrist, 553
skeletal status in, 66
steroid-induced bone loss in, 552
synovial iron deposition in, 298
thoracic duct lymphocyte drainage in, 562
and uridine incorporation into RNA of cultured cells, 419
vasculitis in, immunopathogenesis of, 576
virologic studies in, 446
 in Yakima Indians, 743
Rheumatoid biologically active factor (RBAF), related to
 clinical status, 225
Rheumatoid factors
 immunofluorescence for detection of, 59
 low affinity, interaction with IgG antigens, 573
 peptide reactive with, 134
 triclonal gammopathy, 135
Rheumatoid synovial collagenase, affecting cartilage collagen fibrils, 552
Rheumatologists, certification of, 771

RNA
 antibodies to, in SLE, 554
 of cultured rheumatoid cells, uridine incorporation into, 419
protein antigen, in SLE serum, 124
reovirus, antibodies to, in SLE, 383, 719

S

Salicylates
 and enzyme release from leukocytes in phagocytosis, 749
 genetic control of metabolism of, 550
 hepatotoxicity in juvenile RA, 1
 interactions with fenoprofen, 635
Scanning
 brain, in lupus cerebritis, 534
 of femoral head, in vascularity studies, 539
School achievement, and serum uric acid, 359
Scleroderma
 calcinosis in, 542
and effects of cyclophosphamide on lymphocytes, 554
finger capillary abnormalities in, 619
hemodialysis and kidney transplantation in, 265
kidney in, 556
pericardial disease in, 559
Serologic data, comparisons of, 701
Schwartzman reaction, induced in 6-sulfanilamidoindazole
 arthritis, 491
Siblings, lupus erythematosus in, 221
Sjogren's syndrome
 in juvenile RA, 122
 marrow granulocyte reserves in, 345
 outpatient study of, 574
Skeletal status, in RA, 66
Skin
 experimental lesions resembling SLE, 579
 immunoglobulin deposits in SLE, 564
Spine
 hyperostosis in Pima Indians, 114
 intervertebral disc space infections in heroin addicts, 562
Spondylitis, ankylosing
 bowel in, 549
 genetic studies of, 573
 and HL-A antigen W27, 568
Staphylococci, acute infectious arthritis from, 547
Sterility rate, and lupus erythematosus, 541
Steroids. *See* Corticosteroids
Still's disease. *See* Rheumatoid arthritis, juvenile
Streptococci, acute infectious arthritis from, 547
6-Sulfanilamidoindazole arthritis, and induction of
 Schwartzman reaction, 491
Surgery
 drainage in acute infectious arthritis, versus medical treatment, 547

hip replacement, and thromboembolic disease, 117
knee replacement with prostheses, 532, 533
partial meniscectomy, degenerative lesions after, 397
reconstruction of rheumatoid wrist, 553

Synovial cells
changes in organ culture, 324
cultured JRA, virus replication in, 714
prostaglandin synthesis by cultures, colchicine affecting, 129
rheumatoid
culture of B-immunocytes, 341
uridine incorporation into RNA of, 419

Synovial cysts of elbow, valvular mechanisms in, 259

Synovial fluid
calcium pyrophosphate crystals in, in ochronotic arthropathy, 705
cryoglobulins activating alternate pathway of complement, 575
detection of trace amounts of, 487
immune complexes in, 10
inorganic phosphate levels in pseudogout and osteoarthritis, 570
lactoferrin in, 186
lipid effusion in SLE, 759
lymphocytes in early RA, 544
proportion of B and T lymphocytes in RA, 138
pyrophosphate in, in pseudogout, 171
rheumatoid, collagenase affecting cartilage collagen fibrils in, 552

Synovial membrane
acid phosphatase in, and clinical disease, 376
in ferritin-induced arthritis, 733
in hepatitis, and Australia antigen, 543
rheumatoid
iron deposition in, 298
lymphoid cells in, 471

Synovitis
acute, immunologically induced, 10
lymphokine-induced, 121
urate crystal-induced, cyclic AMP affecting, 136

T

Temporal arteries, immunoglobulins in, 557
Thoracic duct lymphocytes, drainage in RA, 562
Thromboembolic disease, and total hip replacement, 117
Thymocytotoxic antibody, of NZB mice, 561
Toxoplasmosis, in polyomyositis, 555
Transplantation and hemodialysis of kidney
in lupus nephritis, 117
in scleroderma, 265

Tuberculosis
and bacterial arthritis, 543
with viral hepatitis and SLE, 406

Tumor development, after cyclophosphamide, 524

Twins, calcific periarthritis in, 393

U

Urate crystals
with adsorbed endotoxin, and gout induction, 575
inducing arthritis, in animals lacking Hageman factor, 571
inducing chemotaxis, 571
inducing synovitis, cyclic AMP affecting, 136

Urate sodium
binding to serum albumin, 537
lysosomal enzyme release by, 132

Uremia, plasma PPi in, 132

Uric acid
estimation of secretion, 539
gouty hyperuricemia, single daily dose of allopurinol in, 128
nicotinic acid affecting metabolism of, 545
serum levels
and achievement in high school, 359
glycopyrrolate affecting, 127
suppression of secretion in renal hypouricemia, 570

Uridine incorporation, into RNA of cultured rheumatoid cells, 419

Urinary metabolites of hydralazine, in SLE, 217

V

Valvular disease, rheumatic, pathogenesis of, 122

Valvular mechanisms, in antecubital cysts in RA, 259

Vasculitis
with monoclonal IgG cryoglobulinemia, 548
in rheumatoid arthritis, immunopathogenesis of, 576

Venography, intraosseous, of osteoarthritic knee, 124

Viruses
antibodies to viral RNA in SLE, 383, 719
antibody levels in juvenile RA, 126
arthritis from Herpes simplex virus, 241, 533
in connective tissue diseases, 125, 677
Epstein-Barr virus antibody in SLE, 97
in hepatitis with tuberculosis and SLE, 406
replication in cultured JRA synovial cells, 714
studies in RA, 446
studies of uridine incorporation into RNA of cultured rheumatoid cells, 419

W

Wegener's granulomatosis, cyclophosphamide in, 657

Wrist, rheumatoid, reconstruction of, 553

Y

Yakima Indians, rheumatoid arthritis in, 743





arthritis and rheumatism

Official Journal of The American Rheumatism Association
Section of The Arthritis Foundation

VOLUME 16, 1973



Medical Department
HARPER & ROW, PUBLISHERS, INC.
Hagerstown, Md.

ARTHRITIS AND RHEUMATISM

EDITOR

Charles L. Christian, MD

EDITORIAL BOARD

K. Frank Austen, MD, Boston

J. Claude Bennett, MD, Birmingham

John J. Calabro, MD, Worcester

Alan S. Cohen, MD, Boston

John L. Decker, MD, Bethesda

Evelyn V. Hess, MD, Cincinnati

David S. Howell, MD, Miami

Gene G. Hunder, MD, Rochester

William H. Kammerer, MD, New York

William N. Kelley, MD, Durham

David Koffler, MD, New York

Stephen M. Krane, MD, Boston

Henry G. Kunkel, MD, New York

Henry J. Mankin, MD, Boston

Mart Mannik, MD, Seattle

William Martel, MD, Ann Arbor

Gerald P. Rodnan, MD, Pittsburgh

John T. Sharp, MD, Houston

Charles D. Tourtellotte, MD, Philadelphia

Ralph C. Williams, Jr, MD, Albuquerque

Nathan J. Zvaifler, MD, San Diego

COMMITTEE FOR THE PUBLICATION OF

Arthritis and Rheumatism

Giles Bole, MD, Chairman, Ann Arbor

John Sharp, MD, Houston

K. Frank Austen, MD, Boston

J. Donald Smiley, MD, Dallas

John S. Davis, MD, Charlottesville

Norman Talal, MD, San Francisco

Copyright © 1973 by The Arthritis Foundation, New York, N.Y.

All rights reserved

CONTENTS

NO. 1 (JANUARY-FEBRUARY)

Salicylate Hepatotoxicity in Patients with Juvenile Rheumatoid Arthritis <i>Robert R. Rich and John S. Johnson</i>	1
Immunologically Induced Acute Synovitis in Rabbits: Studies of Immune Complexes in Synovial Fluid <i>J. Roger Hollister, George C. Liang and Mart Mannik</i>	10
Experimental Bedsonial Arthritis <i>D. Edwards Smith, Paul G. James, Julius Schachter, Ephraim P. Engleman and Karl F. Meyer</i>	21
Antibiotic Therapy in Experimental Bedsonial Arthritis <i>Robert J. Gilbert, Julius Schachter, Ephraim P. Engleman and Karl F. Meyer</i>	30
Immune Response of Patients with Rheumatoid Arthritis During Cyclophosphamide Treatment <i>John E. Curtis, John T. Sharp, Martin D. Lidsky and Evan M. Hersh</i>	34
An Antibody-Like Material in Systemic Lupus Erythematosus Directed Toward a Thermolabile Serum Macroprotein <i>Wallace V. Epstein and Margaret Tan</i>	43
Detection of Circulating DNA by Counterimmunoelectrophoresis (CIE) <i>Gene L. Davis, Jr and John S. Davis, IV</i>	52
An Immunofluorescent Method for the Detection of Antigammaglobulin Antibodies <i>Dorothy Estes, Edgar Atra and André Peltier</i>	59
Skeletal Status in Rheumatoid Arthritis: A Preliminary Report <i>Mark N. Mueller and John M. Juris</i>	66
The Effect of a Cobra Venom Factor on Complement and Adjuvant-Induced Disease in Rats <i>Lygeri Kourounakis, R.A. Nelson, Jr and M.A. Kupusta</i>	71
ARA Symposium: Cytotoxic Drugs in Rheumatic Diseases	77-96
Chemical Action and Pharmacology of Methotrexate, Azathioprine and Cyclophosphamide in Man <i>Joseph R. Bertino</i>	79
Immunosuppressive and Antiinflammatory Properties of Cyclophosphamide, Azathioprine and Methotrexate <i>Eric R. Hurd</i>	84
Toxicity of Immunosuppressive Drugs in Man <i>John L. Decker</i>	89

Efficacy of Immunosuppressive Drugs in Rheumatic Diseases
Alfred D. Steinberg

92

Epstein-Barr Virus Antibody Levels in Systemic Lupus Erythematosus
Paul E. Phillips and Yashar Hirshaut

97

Brief Communication
Fender-Kicker Syndrome
C. Douglas Angevine, Edward C. Atwater and Ralph F. Jacob

102

ARA Presidential Address
The Fortieth
J. Sydney Stillman

106

ARA News
Abstracts

112

113

NO. 2 (MARCH-APRIL)

Treatment of Psoriatic Arthritis With 6-Mercaptopurine
John Baum, Eric Hurd, David Lewis, John L. Ferguson and Morris Ziff

139

Double-Blind Study of Cyclophosphamide in Rheumatoid Arthritis
Martin D. Lidsky, John T. Sharp and Sharon Billings

148

Cyclophosphamide Therapy in Systemic Lupus Erythematosus and Polymyositis
James F. Fries, Gordon C. Sharp, Hugh O. McDevitt and Halsted R. Holman

154

Comparison of Therapeutic and Immunosuppressive Effects of Azathioprine, Prednisolone and Combined Therapy in NZB/NZW Mice
Bevra H. Hahn, Mary K. Bagby, Tom R. Hamilton and C. Kirk Osterland

163

Articular Chondrocalcinosi: Microanalysis of Pyrophosphate (PPi) in Synovial Fluid and Plasma
Roy D. Altman, Ofelia E. Muniz, Julio C. Pita and David S. Howell

171

Degradation of Proteoglycans in Human Osteoarthritis Cartilage
Roy D. Altman, Julio C. Pita and David S. Howell

179

Lactoferrin—An Iron Binding Protein in Synovial Fluid
Robert M. Bennett, A. C. Eddie-Quartey and P. J. L. Holt

186

Studies on the Infectious Etiology of Rheumatoid Arthritis
B. C. Cole, J. R. Ward and C. B. Smith

191

A Millipore Filter Assay for Antibodies to Native DNA in Sera of Patients with Systemic Lupus Erythematosus
Barry Ginsberg and Harold Keiser

199

Mechanisms of Release of Granule Enzymes from Human Neutrophils Phagocytosing Aggregated Immunoglobulin: An Electron Microscopic Study <i>Peter M. Henson</i>	208
Hydralazine Urinary Metabolites in Systemic Lupus Erythematosus <i>Allen Litwin, Louis E. Adams, Evelyn V. Hess, Joseph McManus and Hans Zimmer</i>	217
Report of the Familial Occurrence of Systemic Lupus Erythematosus in Male Siblings <i>David A. Spector, Lee M. Jampol and John P. Hayslett</i>	221
Studies Into the Occurrence of Soluble Antigen-Antibody Complexes in Disease: V. Second Assessment of Correlation Between the Rheumatoid Biologically Active Factor (RBAF) and the Clinical Features of Rheumatoid Arthritis <i>Murray B. Urowitz, Duncan A. Gordan and Irvin Broder</i>	225
Influence of Natural and Synthetic Estrogens on the Course of Autoimmune Disease in the NGB/NZW Mouse <i>Sara Ellen Walker and Giles G. Bole, Jr</i>	231
Experimental Viral Arthritis Induced With Herpes Simplex <i>Francis W. Webb, Rodney Bluestone, Leonard S. Goldberg, Steven D. Douglas and Carl M. Pearson</i>	241
Prostaglandin E₁ (PGE₁) Suppression of Adjuvant Arthritis: Histopathology <i>Robert B. Zurier and Maurice Ballas</i>	251
Brief Communication	
Valvular Mechanisms in Antecubital Cysts of Rheumatoid Arthritis <i>George E. Ehrlich and Gad G. Guttman</i>	259
Arthritis Rounds	
Hemodialysis and Kidney Transplantation for Renal Failure from Scleroderma <i>James A. Richardson</i>	265
Discussion	
Gerald P. Rodman	268
E. Carwile LeRoy	270
Candida guilliermondi Infection of the Knee Complicating Rheumatoid Arthritis: A Case Report <i>D. R. Graham and H. M. Frost</i>	272
Discussion <i>Donald B. Louria</i>	276
Psoriatic Arthritis in a Child <i>C. Douglas Angevine, I. Barry Pless, John Baum and Ralph F. Jacob</i>	278
Discussion <i>Barbara M. Ansell</i> <i>John J. Calabro</i>	281
Book Reviews	
Beyond the Copper Bracelet: What You Should Know About Arthritis	284
Immunology, Immunopathology and Immunity	284
ARA News	285

NO. 3 (MAY-JUNE)

Immunopathologic Significance of Cartilage Antigenic Components in Rheumatoid Arthritis

Jerome H. Herman, David W. Wiltse and Marie V. Dennis 287

Synovial Iron Deposition in Rheumatoid Arthritis

Robert M. Bennett, E. D. Williams, S. M. Lewis and P. J. L. Holt 298

The Arthropathy of Hemochromatosis Without Hemochromatosis

Duncan A. Gordon and Hugh A. Little 305

Abnormal Structures in Circulating Lymphocytes from Patients with Systemic Lupus Erythematosus and Related Diseases

Philip M. Grimley, John L. Decker, Herman J. Michelitch and Molly M. Frantz 313

Fine Structural Analysis of Rabbit Synovial Cells. I. The Normal Synovium and Changes in Organ Culture

Phoebe R. Krey and Alan S. Cohen 324

Continuous Culture of a B-Immunocyte from Rheumatoid Synovium

Denys K. Ford and J. Donald Smiley 341

Marrow Granulocyte Reserves in the Rheumatic Diseases

Harry R. Kimball, Sheldon M. Wolff, Norman Talal, Paul H. Plotz and John L. Decker 345

A Controlled Trial of Gold Salt Therapy in Rheumatoid Arthritis

The Cooperating Clinics Committee of the AMERICAN RHEUMATISM ASSOCIATION 353

Serum Uric Acid and Achievement in High School

Henry J. Montoye and William M. Mikkelsen 359

Regional Migratory Osteoporosis

Ramesh C. Gupta, Mordecai M. Popovtzer, William E. Huffer and Charley J. Smyth 363

Relative T-Cell Specificity of Lymphocytotoxins from Patients with Systemic Lupus Erythematosus

Richard B. Lies, Ronald P. Messner and Ralph C. Williams, Jr 369

Correlation of Histochemical, Histologic and Biochemical Evaluations of Human Synovium with Clinical Activity

Bruce A. Waxman and Clement B. Sledge 376

Antibodies to Viral and Synthetic Double-Stranded RNA in Discoid Lupus Erythematosus

Robert A. Sylvester, Moises Attias, Norman Talal and Denny L. Tuffanelli 383

Polyarthritides and Subcutaneous Nodules Associated with Carcinoma of the Pancreas

Arthur M. Virshup and Anthony J. Sliwinski 388

Calcific Periarthritis Involving Multiple Sites in Identical Twins <i>Richard B. Cannon and Frank R. Schmid</i>	393
Experimentally Induced Degenerative Joint Lesions Following Partial Meniscectomy in the Rabbit <i>Roland W. Moskowitz, Wirt Davis, James Sammarco, Mark Martens, Jack Baker, Michael Mayor, A. H. Burstein and V. H. Frankel</i>	397
Serologic Abnormalities in Systemic Lupus Erythematosus Associated with Viral Hepatitis and Tuberculosis <i>Kent W. Salisbury, Paul H. Plotz, Paul V. Holland, Alfred D. Steinberg and Mark Peppercorn</i>	406
Azathioprine in Rheumatoid Arthritis: A Double-Blind, Cross-Over Study <i>Murray B. Urowitz, Duncan A. Gordon, Hugh A. Smythe, Waldemar Pruzanski and Metro A. Ogryzlo</i>	411
Brief Communication Uridine Incorporation into the Media and RNA of Cultured Rheumatoid Synovial Cells <i>Arthur I. Grayzel</i>	419
Current Comment Lymphocyte Heterogeneity and Function <i>Norman Talal</i>	422
Drug Letter Mexicali Treatment of Rheumatoid Arthritis <i>L. A. Healey</i>	426
Letters	428
ARA News	430

NO. 4 (JULY-AUGUST)

The Past Four Decades of Progress in the Knowledge of Gout, With an Assessment of the Present Status <i>Alexander B. Gutman</i>	431
Virologic Studies on Rheumatoid Arthritis <i>R. Michael Wilkes, James P. Simsarian, Hope E. Hopps, Henry Roth, John L. Decker, Robert G. Aptekar, and Harry M. Meyer, Jr</i>	446
Differing Effects of Azathioprine and Cyclophosphamide on Immune Responses to Flagellin in Man <i>Ian R. Mackay, John M. Dwyer, and Merrill J. Rowley</i>	455
Bladder Toxicity With Chronic Oral Cyclophosphamide Therapy in Non-malignant Disease <i>Robert G. Aptekar, MD, John P. Atkinson, MD, John L. Decker, MD, Sheldon M. Wolff, MD, and Elizabeth W. Chu, MD</i>	461

Preparation of ^{125}I-Labeled Native DNA for Use in Radioimmunoassays for Anti-Native-DNA Antibodies <i>Harold Keiser</i>	468
Electron Microscopic Studies of Lymphoid Cells in the Rheumatoid Synovial Membrane <i>Ikuo Kobayashi and Morris Ziff</i>	471
Rapid, Simple Detection of Trace Amounts of Synovial Fluid <i>Don L. Goldenberg, Kenneth D. Brandt, and Alan S. Cohen</i>	487
Local and Generalized Shwartzman Reaction Induced in Rats With 6-Sulfanilamidoindazole Arthritis <i>John R. Ward, Morgan L. Miller, and Frank Burch</i>	491
Cellular Immunity in Rheumatic Diseases. I. Rheumatoid Arthritis <i>Jack Waxman, Michael D. Lockshin, Jerome J. Schnapp, and Ira N. Donegan</i>	499
The Fourth Component of Complement in the Cerebrospinal Fluid in Systemic Lupus Erythematosus <i>Nortin M. Hadler, Robert D. Gerwin, Michael M. Frank, John N. Whitaker, Max Baker, and John L. Decker</i>	507
Memorial to Alexander B. Gutman	522
Letters	524
Book Reviews	528
ARA News	530
Abstracts	532

NO. 5 (SEPTEMBER-OCTOBER)

Experimental Skin Lesions in Mice Resembling Systemic Lupus Erythematosus <i>P. G. Natali and E. M. Tan</i>	579
Serum Parathyroid Hormone Levels in Patients With Calcium Pyrophosphate Crystal Deposition Disease (Chondrocalcinosis, Pseudogout) <i>Paulding Phelps and Charles D. Hawker</i>	590
Inhibition of Mixed Leukocyte Culture Responses by Serum and γ-Globulin Fractions From Certain Patients With Connective Tissue Disorders <i>Ralph C. Williams, Jr., Richard B. Lies, and Ronald P. Messner</i>	597
Suppression of Acute and Chronic Inflammation in Adrenalectomized Rats by Pharmacologic Amounts of Prostaglandins <i>Robert B. Zurier, Sylvia Hoffstein, and Gerald Weissmann</i>	606
Patterns of Finger Capillary Abnormalities in Connective Tissue Disease by "Wide-Field" Microscopy <i>Hildegard Rand Maricq and E. Carwile LeRoy</i>	619

Fenoprofen® Calcium in Rheumatoid Arthritis: A Controlled Double-Blind Cross-over Evaluation	
<i>James F. Fries and Melvin C. Britton</i>	629
Interactions of Aspirin With Nonsteroidal Antiinflammatory Drugs in Man	
<i>Alan Rubin, Bruce E. Rodda, Patricia Warrick, Charles M. Gruber, Jr., and Anthony S. Ridolfo</i>	635
The Effect of Low Oxygen Concentration on Growth, Glycolysis, and Sulfate Incorporation by Articular Chondrocytes in Monolayer Culture	
<i>Ralph E. Marcus</i>	646
The Effect of Cyclophosphamide on Leukocyte Kinetics and Susceptibility to Infection in Patients With Wegener's Granulomatosis	
<i>David C. Dale, Anthony S. Fauci, and Sheldon M. Wolff</i>	657
Destructive Polyarthritis Secondary to <i>Mycobacterium kansasii</i>	
<i>Donald E. Girard, Grover C. Bagby, Jr., and John R. Walsh</i>	665
Renal Histology and Clinical Course of Systemic Lupus Erythematosus: A Prospective Study	
<i>Don E. Cheatum, Eric R. Hurd, Stanley W. Strunk, and Morris Ziff</i>	670
A Search for Viruses and Mycoplasmas in Connective Tissue Diseases	
<i>Donald A. Person, John T. Sharp, and William E. Rawls</i>	677
Cell-Mediated Immune Response in Systemic Lupus Erythematosus: <i>In vitro</i> Cellular Response to Native DNA by Macrophage Inhibitory Test	
<i>Tohru Abe, Masako Hara, Kuniomi Yamasaki, and Mitsuo Homma</i>	688
A Fatal Case of Reiter's Disease Complicated by Amyloidosis	
<i>David E. Caughey and Christopher J. Wakem</i>	695
Letters	701
Book Reviews	703
ARA News	704

NO. 6 (NOVEMBER-DECEMBER)

Ochronotic Arthropathy With Calcium Pyrophosphate Crystal Deposition: A Light and Electron Microscopic Study	
<i>Antonio J. Reginato, H. Ralph Schumacher, and Virginia A. Martinez</i>	705
Adult Onset Juvenile Rheumatoid Arthritis	
<i>Robert G. Aptekar, John L. Decker, Joseph S. Bujak, and Sheldon M. Wolff</i>	715
Filter Radioimmunoassay for Antibodies to Reovirus RNA in Systemic Lupus Erythematosus	
<i>Moises R. Attias, Robert A. Sylvester, and Norman Talal</i>	719

Nucleolar Antigen Specific for Antinucleolar Antibody in the Sera of Patients With Systemic Rheumatic Disease	
<i>Shoji Miyawaki and Robert F. Ritchie</i>	726
Prevalence of Rheumatoid Arthritis in Alaskan Eskimos	
<i>R. Palmer Beasley, Henry Retaillau, and L. A. Healey</i>	737
High Prevalence of Rheumatoid Arthritis in Yakima Indians	
<i>R. Palmer Beasley, Robert F. Willkens, and Peter H. Bennett</i>	743
Mobilization and Extracellular Release of Granular Enzymes From Human Leukocytes During Phagocytosis: Inhibition by Colchicine and Cortisol but Not by Salicylate	
<i>Daniel G. Wright and Stephen E. Malawista</i>	749
Arthritis Rounds	
Lipid Synovial Effusion: Unique Occurrence in Systemic Lupus Erythematosus	
<i>William E. Ryan, Ralph D. Ellefson, and L. Emmerson Ward</i>	759
ARA Presidential Address	
The Final Common Pathway	
<i>John L. Decker</i>	765
Editorial	
Rheumatologists by Certification or by Reputation	
<i>Joseph Lee Hollander</i>	771
Drug Letter	
Generic Equivalents	
<i>L. A. Healey</i>	775
Letters	776
Book Reviews	779
ARA News	781
Annual Indexes	
Authors	783
Subjects	791

